Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19143504 | 0.87 | POLB (0.33) | MAPK1NPSR1 | |
| SCHEMBL19550516 | 0.80 | POLB (0.35) | — | |
| SCHEMBL19550513 | 0.80 | POLB (0.35) | — | |
| SCHEMBL19550982 | 0.80 | POLB (0.35) | — | |
| Hydrochloric Acid SCHEMBL19551072 | 0.79 | POLB (0.35) | — | |
| Hydrochloric Acid SCHEMBL19550619 | 0.79 | POLB (0.35) | — | |
| Hydrochloric Acid SCHEMBL19550618 | 0.79 | POLB (0.35) | — | |
| SCHEMBL17225276 | 0.76 | CA2 (0.38) | CA2MAPK1NPSR1CA1 | |
| SCHEMBL4184435 | 0.76 | GAA (0.35) | CA2 | |
| SCHEMBL15804441 | 0.75 | APLNR (0.33) | MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3535255-A1 | PYRIDAZINE DERIVATIVES AS RORC MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | RORC, RORB, RORA | CA2 3183/4885MAPK1 1613/4885NPSR1 38/4885 |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | CA2 3183/4885MAPK1 1613/4885NPSR1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.